Celcuity (CELC) stock
Pro members see every stock ranked and every check behind each score, live.
Why it's down
Down 30% in 3 months, 14% under its 50-day average.
Its industry held up: the 16 other stocks in it rose a median 10% over the same 3 months.
−2Dilution 25.5% more shares outstanding than a year ago
4 more things pulling CELC's score down, for Pro members
What's next
Expected to report Wed Nov 11, after the close
After its last 4 reports it closed +3.4% on average, higher 4 of 4 times.
What would turn CELC's score around: 8 things, for Pro members
Here is what Pro members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
CELC has 2 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1431.2
- MACD (12, 26, 9)Below signal
- 50-day average$87.28
- 200-day average$104.43
- ADX 1421.3
- Support$71.06
- Resistance$83.00
- Bollinger Bands (20, 2)Inside
- Volume1.5x
How CELC ranks in Diagnostics
CELC is #17 of 17 by Quality Score among Services-Medical Laboratories. The top three are shown with their scores, and more by name.
CDNA9/1421
NTRA7/1419
GH7/1416
CAIOpen for its score
DGXOpen for its score
FTREOpen for its score
CELC2/14-4
When does CELC report earnings, and what happens after?
Expected to report Wed Nov 11, after the close (in 40 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 13, 2026After close | After close | -4.1% | +6.2% | +4.6% |
| May 14, 2026After close | After close | -3.4% | +2.2% | +5.8% |
| Mar 25, 2026After close | After close | -0.9% | +4.2% | +2.5% |
| Nov 12, 2025After close | After close | 0.0% | +1.0% | +10.7% |
Who is trading CELC
CELC insider trades
One insider sold $318M across 2 filings in the last 6 months. No open-market buys on record. The newest:
About Celcuity
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of CELC's score, with the points and the reason
- All 14 checks on CELC and on all 2,960 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on CELC
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.